ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

IL15

interleukin 15 · also IL-15, MGC9721 · Interleukins

6 programs in company-led studies act on IL15, from 6 companies: 2 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
nogapendekin alfa inbakiceptruleImmunityBioagonistphase 34511 runningIL15RA, IL2RB, IL2RGNCIt
efserakefusp alfaJiangsu HengRui Medicine–phase 364 running–the company's pipeline
belacabnagene franleucelruleNkarta–phase 233 runningCD19NCIt
GIA632Novartis–phase 233 running–the company's pipeline
SPGL008rule3SBio–phase 233 runningIL15RAthe studies' text
Daxokafusp AlfaSanofi–phase 222 runningIL2, PDCD1the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.